<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428842</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2013-02 BIO-RAIDs</org_study_id>
    <nct_id>NCT02428842</nct_id>
  </id_info>
  <brief_title>Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B2 - 4)</brief_title>
  <acronym>BIO-RAIDs</acronym>
  <official_title>Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B2 - 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Multicentric European trial for Cervical cancer, not previously treated, with
      tumour biopsies, and blood collection for molecular analysis at predetermined time points.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Correlation between tumor biological profile and treatment response.</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dominant mutations and activation pathways in cervical cancers is assessed from tumor biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival evaluation</measure>
    <time_frame>up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patient with no local/metastasis relapse 18 months after end of primary treatment course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard treatment description (Description of primary treatment course regarding : - Initial FIGO ( International Federation of Gynecology and Obstetrics  ) staging at baseline - Geographic location(country)</measure>
    <time_frame>up to six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Description of primary treatment course regarding :
Initial FIGO ( International Federation of Gynecology and Obstetrics
) staging at baseline
Geographic location(country)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard treatment's side effects description (assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale - National Cancer Institute Common Toxicity Criteria for Adverse Effects)</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Description of standard treatment's side effects will be assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular tumor alterations description (Description of molecular tumor alterations regarding geographic location (country)</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Description of molecular tumor alterations regarding geographic location (country)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient will undergo standard care with tumor and blood sampling before and after treatment.
Blood and tumor sampling will also be performed at disease progression/relapse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsies</intervention_name>
    <description>Tumor biopsies will be performed before and after treatment.</description>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling will be performed before and after treatment.</description>
    <arm_group_label>Tumor biopsies and blood sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No prior treatment for cervical cancer.

          2. FIGO Stage IB2 to IVB; all histological subtypes (excluding neuro-endocrine type).

          3. Pelvic MRI available or planned before the start of treatment.

          4. Possibility to communicate imaging data by CD-ROM (format DICOM 3.0 or more).

          5. Disease amenable to biopsy (3 tumour samples are mandatory prior to treatment).

          6. Age ≥ 18 years.

          7. ECOG (Eastern Cooperative Oncology Group) 0-2.

          8. Life expectancy &gt; 6 months.

          9. Patient eligible for standard treatment (according to standards of each center).

         10. Patient having health care insurance.

         11. Informed and signed consent by patient.

        (DICOM = Digital Imaging and Communications in Medicine)

        Exclusion Criteria:

          1. Patient enrolled in a clinical trial involving an investigative new agent.

          2. Co morbidity, preventing patient to tolerate the proposed standard treatment.

          3. Past history of invasive cancer over the 5 years preceding entry in the present trial
             (except basal cell carcinoma and carcinoma in situ of the cervix).

          4. Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker,
             metallic implant, non availability, other).

          5. Patient deprived from ability to decide on her own.

          6. Patient unable to have a regular follow up for geographical, social or psychological
             reasons.

          7. Pregnancy or patient old enough to procreate and not using effective contraceptive
             method.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patricia TRESCA, MD.</last_name>
    <phone>+33 1.56.24.56.49</phone>
    <email>chrystelle.gastrin@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Bichat</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin KOSKAS, MD</last_name>
      <phone>0140258080</phone>
      <email>martin.koskas@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Martin KOSKAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie IMESGOUEZ-NEBOUT, MD</last_name>
      <phone>0241352734</phone>
      <email>nathalie.mesgouez-nebout@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie MESGOUEZ-NEBOUT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric GUYON, MD</last_name>
      <phone>05.56.33.78.30</phone>
      <email>guyon@bergonie.org</email>
    </contact>
    <investigator>
      <last_name>Frédéric GUYON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles COUTANT, MD</last_name>
      <phone>03.80.73.75.00</phone>
      <email>ccoutant@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Charles COUTANT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas CHOPIN, MD</last_name>
      <phone>04 78 78 51 29</phone>
      <email>nicolas.chopin@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas CHOPIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer de Montpellier - Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Emmanuel COLOMBO, MD</last_name>
      <phone>01467613114</phone>
      <email>pierre-emmanuel.colombo@icm.montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Emmanuel COLOMBO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine - ICL</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric MARCHAL, MD</last_name>
      <phone>03 83 59 84 51</phone>
      <email>f.marchal@nancy.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric MARCHAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc CLASSE, MD</last_name>
      <phone>02.40.67.99.10</phone>
      <email>jean-marc.classe@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc CLASSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LECURU, MD</last_name>
      <phone>0156093584</phone>
      <email>fabrice.lecuru@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice LECURU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emile DARAI, MD</last_name>
      <phone>0156017318</phone>
      <email>emile.darai@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emile DARAI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte NGO, MD</last_name>
      <phone>01.47.11.15.15</phone>
      <email>charlotte.ngo@curie.net</email>
    </contact>
    <investigator>
      <last_name>Charlotte NGO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman ROUZIER, MD</last_name>
      <phone>01 47 11 15 15</phone>
      <email>roman.rouzier@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Roman ROUZIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Stransbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine HAIE MEDER, MD</last_name>
      <phone>01.42.11.45.66</phone>
      <email>christine-haie@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Christine HAIE MEDER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mhh Hanover - Hanover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter HILLEMANNS, MD</last_name>
      <email>hillemanns.peter@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Peter HILLEMANNS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <state>Meibergdreef</state>
        <zip>91105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma KENTER, MD</last_name>
      <email>g.kenter@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Gemma KENTER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherland Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1006 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma KENTER, MD</last_name>
      <email>g.kenter@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Gemma KENTER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teo Health S.A. - Spitalul Sf. Constantin</name>
      <address>
        <city>Brasov</city>
        <zip>500091</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugeniu BANU, MD</last_name>
      <email>eugeniu.banu@spitalulsfconstantin.ro</email>
    </contact>
    <investigator>
      <last_name>Eugeniu BANU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal &quot;Gavril Curteanu&quot;</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeta PATCAS, MD</last_name>
      <email>elipatcas@mail.com</email>
    </contact>
    <investigator>
      <last_name>Elisabeta PATCAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica de radioterapie</name>
      <address>
        <city>Timisoara</city>
        <zip>300041</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sorin DEMA, MD.</last_name>
      <email>xrtsdema@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sorin DEMA, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic for operative oncology, Institute of oncology of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina POPOVIC, MD</last_name>
      <email>popovic.marina@onk.ns.rs</email>
    </contact>
    <investigator>
      <last_name>Marina POPOVIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 23, 2015</lastchanged_date>
  <firstreceived_date>February 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Tumor biopsies</keyword>
  <keyword>Standard treatment</keyword>
  <keyword>Molecular profile</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
